Jump to:
Destiny Pharma PLC Fundamentals
| Company Name | Destiny Pharma PLC | Last Updated | 2024-04-19 |
|---|
| Industry | Biotechnology | Sector | Healthcare |
|---|
| Shares in Issue | 95.312 m | Market Cap | £20.25 m |
|---|
| PE Ratio | 0.00 | Dividend per Share | 0 |
|---|
| Dividend Yield | 0 | Dividend Cover | 0 |
|---|
| EPS | -£0.09 | EPS Growth (%) | 0 |
|---|
| PEG | 0 | DPS Growth (%) | 0 |
|---|
| Debt Ratio | 0 | Debt Equity Ratio | 0 |
|---|
| Asset Equity Ratio | 1.0946 | Cash Equity Ratio | 0.8258 |
|---|
| Quick Ratio | 9.4784 | Current Ratio | 9.48 |
|---|
| Price To Book Value | 1.6992 | ROCE | 0 |
|---|
Destiny Pharma PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Destiny Pharma PLC Company Financials
| Assets | 2022 | 2021 |
|---|
| Tangible Assets | £24,621.00 | £35,882.00 |
| Intangible Assets | £2.26 m | £2.26 m |
| Investments | 0 | 0 |
| Total Fixed Assets | £2.29 m | £2.30 m |
| Stocks | 0 | 0 |
| Debtors | £202,477.00 | £64,657.00 |
| Cash & Equivalents | £4.90 m | £4.65 m |
| Other Assets | 0 | 0 |
| Total Assets | £8.80 m | £8.28 m |
| Liabilities | 2022 | 2021 |
|---|
| Creditors within 1 year | £1.17 m | £773,436.00 |
| Creditors after 1 year | 0 | 0 |
| Other Liabilities | 0 | 0 |
| Total Liabilities | £1.17 m | £773,436.00 |
| Net assets | £7.63 m | £7.51 m |
| Equity | 2022 | 2021 |
|---|
| Called up share capital | £733,071.00 | £598,719.00 |
| Share Premium | £33.04 m | £27.09 m |
| Profit / Loss | -£7.71 m | -£6.27 m |
| Other Equity | £7.63 m | £7.51 m |
| Preference & Minorities | 0 | 0 |
| Total Capital Employed | £7.63 m | £7.51 m |
| Ratios | 2022 | 2021 |
|---|
| Debt Ratio | 0 | 0 |
| Debt-to-Equity | 0 | 0 |
| Assets / Equity | 1.0946 | 1.0946 |
| Cash / Equity | 0.8258 | 0.8258 |
| EPS | -£0.09 | -£0.09 |
| Cash Flow | 2022 | 2021 |
|---|
| Cash from operating activities | -£5.89 m | -£5.09 m |
| Cashflow before financing | £194,166.00 | -£5.08 m |
| Increase in Cash | £257,899.00 | -£5.10 m |
| Income | 2022 | 2021 |
|---|
| Turnover | 0 | 0 |
| Cost of sales | 0 | 0 |
| Gross Profit | 0 | 0 |
| Operating Profit | -£7.78 m | -£6.29 m |
| Pre-Tax profit | -£7.71 m | -£6.27 m |
Destiny Pharma PLC Company Background
| Sector | Healthcare |
|---|
| Activities | Destiny Pharma PLC is a clinical-stage biotechnology company which is focused on the development of medicines for the treatment of infectious disease. It is developing drugs for the prevention and treatment of infections caused by Antibiotic-Resistant (AR) bacteria. It is involved in developing XF-73 Dermal for the treatment of skin infections of antibiotic-resistant bacteria, XF-73 Nasal for prevention of post-surgical staphylococcal infection, XF Throat for prevention of staphylococcal hospital/ventilator-associated pneumonia infection. |
|---|
| Latest Interim Date | 20 Sep 2023 |
|---|
| Latest Fiscal Year End Date | 25 Apr 2024 |
|---|
Destiny Pharma PLC Directors
| Appointed | Name | Position |
|---|
| 2023-07-25 | Sir Anthony Nigel Russell Rudd DL | Non-Executive Director,Chairman |
| 2023-07-25 | Mr. Philip Nicholas Rodgers | Non-Executive Director,Chairman |
| 2023-04-27 | Mr. Nigel Stanley Brooksby | Non-Executive Director |
| 2023-05-25 | Mr. Neil Robert Clark | Executive Director,Chief Executive Officer |
| 2018-04-23 | Mr. Simon Sacerdoti | Executive Director,Chief Financial Officer and Company Secretary |
| 2023-10-20 | Mr. Christopher John Tovey | Executive Director,Chief Executive Officer |
| 2023-10-20 | Mr. Shaun Claydon | Executive Director,Chief Financial Officer and Company Secretary |
| 2023-10-20 | Dr. William Guy Love | Executive Director,Chief Scientific Officer |
| 2019-09-23 | Mr. Anthony Joseph Eagle | Non-Executive Director |
| 2022-03-31 | Mr. Peter Morgan | Non-Executive Director |
| 2023-05-26 | Dr. Debra Stephanie Barker | Non-Executive Director |
| 2023-05-26 | Mr. Aled Paton Williams | Non-Executive Director |
Destiny Pharma PLC Contact Details
| Company Name | Destiny Pharma PLC |
|---|
| Address | Unit 36, Sussex Innovation Centre, Science Park Square, Falmer, Brighton, BN1 9SB |
|---|
| Telephone | |
|---|
| Website | https://www.destinypharma.com |
|---|
Destiny Pharma PLC Advisors
